Most cited papers in Multiple Myeloma Research and Treatments
What are the most cited papers in Multiple Myeloma Research and Treatments?
The most cited paper in Multiple Myeloma Research and Treatments is "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" (S. Vincent Rajkumar et al., 2014), with 5,031 citations. Next come "Selective inhibition of BET bromodomains" (4,363) and "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera" (3,573).
Showing 50 of 100 papers. Every paper with more than 967 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S. Vincent Rajkumar et al. · The Lancet Oncology | 26 Oct 2014 | 5,031 |
| 2 | Selective inhibition of BET bromodomains P. Filippakopoulos et al. · Nature | 24 Sep 2010 | 4,363 |
| 3 | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature | 27 Mar 2005 | 3,573 |
| 4 | Artemisinin Resistance in Plasmodium falciparum Malaria Arjen M. Dondorp et al. · New England Journal of Medicine | 29 Jul 2009 | 3,505 |
| 5 | A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders Róbert Královics, Francesco Passamonti, Andreas S. Buser et al. · New England Journal of Medicine | 27 Apr 2005 | 3,491 |
| 6 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Hartmut Döhner et al. · Blood | 7 Jul 2022 | 3,286 |
| 7 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Shaji Kunnathu Kumar et al. · The Lancet Oncology | 26 Jul 2016 | 3,102 |
| 8 | A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Brian G.M. Durie, Sydney E. Salmon · Cancer | Sep 1975 | 3,063 |
| 9 | International Staging System for Multiple Myeloma Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology | 4 Apr 2005 | 2,956 |
| 10 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Jake E. Delmore et al. · Cell | Sep 2011 | 2,889 |
| 11 | International uniform response criteria for multiple myeloma Brian G.M. Durie et al. · Leukemia | 20 Jul 2006 | 2,662 |
| 12 | A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul Gerard Guy Richardson et al. · New England Journal of Medicine | 25 Jun 2003 | 2,656 |
| 13 | Antitumor Activity of Thalidomide in Refractory Multiple Myeloma Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine | 18 Nov 1999 | 2,606 |
| 14 | A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma Michel Attal, Jean-Luc Harousseau, Anne-Marie Stoppa et al. · New England Journal of Medicine | 11 Jul 1996 | 2,583 |
| 15 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Nikhil C. Munshi et al. · New England Journal of Medicine | 24 Feb 2021 | 2,554 |
| 16 | Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma Paul Gerard Guy Richardson et al. · New England Journal of Medicine | 15 Jun 2005 | 2,514 |
| 17 | Thalidomide is an inhibitor of angiogenesis. Robert J. D’Amato, Michael Loughnan, Evelyn A. Flynn et al. · Proceedings of the National Academy of Sciences | 26 Apr 1994 | 2,475 |
| 18 | Review of 1027 Patients With Newly Diagnosed Multiple Myeloma Robert A. Kyle, Morie Abraham Gertz, Thomas Elmer Witzig et al. · Mayo Clinic Proceedings | 2003 | 2,463 |
| 19 | Multiple Myeloma Antonio Pierangelo Palumbo, Kenneth Carl Anderson · New England Journal of Medicine | 16 Mar 2011 | 2,360 |
| 20 | Improved survival in multiple myeloma and the impact of novel therapies Shaji Kunnathu Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood | 2 Nov 2007 | 2,266 |
| 21 | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group Antonio Pierangelo Palumbo et al. · Journal of Clinical Oncology | 3 Aug 2015 | 2,243 |
| 22 | Multiple myeloma Noopur S Raje, Kenneth Carl Anderson · Current Treatment Options in Oncology | Feb 2000 | 2,176 |
| 23 | Identification of a Primary Target of Thalidomide Teratogenicity Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science | 11 Mar 2010 | 2,136 |
| 24 | Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Li Ding et al. · Nature | 2012 | 2,045 |
| 25 | ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research | May 2008 | 1,999 |
| 26 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma Jesús F. San Miguel et al. · New England Journal of Medicine | 27 Aug 2008 | 1,913 |
| 27 | Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science | 29 Nov 2013 | 1,897 |
| 28 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Johannes A. Zuber, Junwei Shi, Eric Wang et al. · Nature | Aug 2011 | 1,895 |
| 29 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Courtney Denton Dinardo, Keith William Pratz, Vinod A. Pullarkat et al. · Blood | 26 Oct 2018 | 1,886 |
| 30 | Phthalimide conjugation as a strategy for in vivo target protein degradation Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science | 21 May 2015 | 1,781 |
| 31 | Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur S Raje et al. · New England Journal of Medicine | May 2019 | 1,775 |
| 32 | High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma J. Anthony Child, Gareth John Morgan, Faith E. Davies et al. · New England Journal of Medicine | 7 May 2003 | 1,774 |
| 33 | Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand Beate Heissig, Koichi Hattori, Sérgio Dias et al. · Cell | May 2002 | 1,753 |
| 34 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja et al. · The Lancet | 24 Jun 2021 | 1,751 |
| 35 | Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas Michio Kawano, Toshio Hirano, Tadashi Matsuda et al. · Nature | Mar 1988 | 1,667 |
| 36 | Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells Robyn Catlett-Falcone, Terry H. Landowski, Marc M. Oshiro et al. · Immunity | 1999 | 1,655 |
| 37 | The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science | 29 Nov 2013 | 1,600 |
| 38 | Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis Marta Seretny, Gillian L. Currie, Emily S. Sena et al. · Pain | 23 Sep 2014 | 1,585 |
| 39 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Panagiotis D. Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood | 15 Sep 2001 | 1,559 |
| 40 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Antonio Pierangelo Palumbo, Asher Alban Chanan-Khan, Katja Christina Weisel et al. · New England Journal of Medicine | 24 Aug 2016 | 1,535 |
| 41 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Teru Hideshima, Paul Gerard Guy Richardson, D Chauhan et al. · PubMed | Apr 2001 | 1,530 |
| 42 | CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology | Sep 1998 | 1,529 |
| 43 | The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma Erming Tian, Fenghuang Zhan, Ronald C. Walker et al. · New England Journal of Medicine | 24 Dec 2003 | 1,517 |
| 44 | Malignant fibrous histiocytoma.An Analysis of 200 Cases Sharon Whelan Weiss, Franz M. Enzinger · Cancer | Jun 1978 | 1,506 |
| 45 | A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle, Terry M. Therneau, S. Vincent Rajkumar et al. · New England Journal of Medicine | 21 Feb 2002 | 1,485 |
| 46 | Initial genome sequencing and analysis of multiple myeloma Michael A. Chapman et al. · Nature | Mar 2011 | 1,472 |
| 47 | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Meletios Athanasios Dimopoulos, Andrew G Spencer, Michael Attal et al. · New England Journal of Medicine | 21 Nov 2007 | 1,463 |
| 48 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Meletios Athanasios Dimopoulos et al. · New England Journal of Medicine | 5 Oct 2016 | 1,454 |
| 49 | Prevalence of Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle, Terry M. Therneau, S. Vincent Rajkumar et al. · New England Journal of Medicine | 29 Mar 2006 | 1,434 |
| 50 | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Shaji Kunnathu Kumar, Angela Dispenzieri, Martha Q. Lacy et al. · Leukemia | 25 Oct 2013 | 1,403 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.